FDA Approves Elamipretide as First Treatment for Barth Syndrome
2025-06-15
Elamipretide (Forzinity) becomes the first disease-specific treatment approved for Barth syndrome, marking a milestone in rare disease peptide therapeutics.
In 2025, the FDA approved elamipretide (Forzinity) as the first disease-specific treatment for Barth syndrome, a rare genetic disorder. Elamipretide is a peptide-based therapeutic that improves muscle strength in adult and pediatric patients weighing 30 kg or more.
The approval highlights the growing impact of peptide-based therapeutics in addressing unmet medical needs for rare diseases. Elamipretide represents a significant milestone as the first targeted treatment for Barth syndrome, which previously had no disease-specific therapies available.
This approval is part of the broader 2025 FDA TIDES harvest, which included five TIDES-based therapeutics: one peptide, three oligonucleotides, and one antibody-drug conjugate containing a peptide payload.
Read Full Source Article